Echo Biotech Co., Ltd, Beijing, China.
The Center for Heart Development, Key Lab of MOE for Development Biology and Protein Chemistry, College of Life Sciences, Hunan Normal University, Changsha, Hunan, China.
J Extracell Vesicles. 2024 Nov;13(11):e70012. doi: 10.1002/jev2.70012.
Extracellular vesicles (EVs) had been described as a next-generation drug delivery system, due to the compelling evidence that they can facilitate the transfer of a variety of biomolecules between cells. The most frequently used strategy for loading protein cargoes is the endogenous engineering of EVs through genetic fusion of the protein of interest (POI) and scaffold proteins with high EV-sorting ability. However, the lack of scaffold proteins had become a major issue hindering the promotion of this technology. Herein, we proposed novel screening criteria that relax the inclusion requirement of candidate scaffold proteins and eventually identified a new scaffold protein, PLXNA1. The truncated PLXNA1 not only inherits the high EV-sorting ability of its full-length counterpart but also allows the fusion expression of POI in both outer surface and luminal areas, individually or simultaneously. In conclusion, our screening criteria expanded the range of potential scaffold proteins. The identified scaffold protein PLXNA1 showed great potential in developing therapeutic EVs.
细胞外囊泡 (EVs) 被描述为下一代药物传递系统,因为有令人信服的证据表明它们可以促进各种生物分子在细胞之间的转移。最常用于装载蛋白质货物的策略是通过将感兴趣的蛋白质 (POI) 和具有高 EV 分拣能力的支架蛋白与 EV 进行内源基因融合来对内源性工程化 EV。然而,支架蛋白的缺乏已成为阻碍该技术推广的主要问题。在此,我们提出了新的筛选标准,放宽了候选支架蛋白的包含要求,最终鉴定出一种新型支架蛋白 PLXNA1。截短的 PLXNA1 不仅继承了全长对应物的高 EV 分拣能力,而且还允许 POI 分别或同时在外表面和腔内部融合表达。总之,我们的筛选标准扩大了潜在支架蛋白的范围。鉴定出的支架蛋白 PLXNA1 在开发治疗性 EV 方面具有巨大潜力。